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ABSTRACT 
In this study we present an innovation in the tumor treatment in vivo mediated by magnetic 
mesoporous silica nanoparticles (MMSNs). This device was built with iron oxide magnetic 
nanoparticles embedded in a mesoporous silica matrix and coated with an engineered 
thermoresponsive polymer. The magnetic nanoparticles act as internal heating sources under an 
alternating magnetic field (AMF) that increase the temperature of the surroundings, provoking 
the polymer transition and consequently the release of a drug trapped inside the silica pores. By a 
synergic effect between the intracellular hyperthermia and chemotherapy triggered by AMF 
application, significant tumor growth inhibition was achieved in 48 hours after treatment. 
Furthermore, the small magnetic loading used in the experiments indicates that the treatment is 
carried out without a global temperature rise of the tissue, which avoids the problem of the 
necessity to employ large amounts of magnetic cores, as is common in current magnetic 
hyperthermia.  
INTRODUCTION 
The lack of selectivity of traditional chemotherapy towards tumor masses can cause serious 
side effects in patients due to the high toxicity of administered anticancer drugs. In addition, this 
poisonous restricts the dosage and diminishes the effectiveness of the treatments. Thanks to their 
nanometer size, the application of nanomaterials in oncology has been revealed as an important 
tool to improve the action of traditional chemotherapy agents in terms of specificity, security and 
bioavailability.1 The preferential accumulation of nanocarriers in solid tumors is a consequence 
of the defective vasculature of cancer tissues derived from the fast growing of the blood vessels 
and enhanced by an inefficient lymphatic drainage, as was revealed by Maeda and Matsumura in 
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 3 
1986. This passive targeting is named enhanced permeation and retention effect (EPR effect).2,3 
One of the challenges of the nanomedicine nowadays is the development of drug delivery 
vehicles with stimuli-responsive properties in order to dispense on demand the transported 
therapeutic agents, reducing the side toxicity and enhancing the solubility and circulation time of 
housed drugs.4–7 Retaining the cytotoxic agents inside the nanocarrier during its travel to the 
cancer tissue, the systemic toxicity of the anticancer drugs can be avoided or decreased which 
results in a significant reduction of the side effects of the treatment. Once the accumulation in the 
tumoral mass has occurred, the presence of certain stimuli fires the triggering mechanism 
provoking the drug departure and consequently, the cancer cell death in a highly localized area. 
Among this field, mesoporous silica nanoparticles (MSNs) have great properties to build stimuli-
responsive drug delivery devices, as high surface area where large amounts of drugs can be 
hosted, ease functionalization of the inner and outer surface by silanol chemistry, and high 
chemical stability.8,9 Different stimuli such as ultrasounds, light, pH, enzymes and others, can be 
used to trigger the drug release from the nanocarrier.10–17 Therefore, it is possible to develop 
specific treatments for the target disease choosing the stimuli that is more convenient depending 
on the pathology characteristics that have to be treated.18 Magnetic fields are non-invasive 
stimulus and possesses a high penetration in tissues which represents an exceptional opportunity 
to develop magnetically triggered drug delivery devices.19–27 To confer magnetic properties to 
the mesoporous silica nanodevices, the inclusion of magnetic nanoparticles (MNPs) in the 
nanocarriers is mandatory to take advantage of its interactions with magnetic fields. These 
interactions lead to interesting possibilities as magnetic targeting through static magnetic 
fields,28,29 magnetic protein separation30 or the one that will be addressed in this study, the 
hyperthermia treatment with alternating magnetic fields (AMF). Hyperthermia have been proved 
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 4 
as an efficient treatment against tumors but, as any other technique, presents some drawbacks 
such as limitations of the AMF generation source or application parameters or the need to 
achieve high concentrations of MNPs in the target tissue.31 At this point, some studies showed 
that it is possible to induce toxicity in cancer cells by hyperthermia, even when the released heat 
does not increase the macroscopic temperature, but it is still a matter of controversy despite of 
some examples showed by different authors.32,33 After a literature examination, the published 
dual treatments combining hyperthermia and chemotherapy with a single nanocarrier, always 
needed a macroscopic temperature rise in order to cause the cancer growth inhibition or 
eradication.34–36 This work presents an innovation in the tumor treatment in vivo mediated by 
magnetic mesoporous silica nanoparticles (MMSNs), by a synergic effect between the 
intracellular hyperthermia and chemotherapy triggered by AMF application. Furthermore, the 
small magnetic loading used in the experiments indicates that the treatment is carried out without 
a global temperature rise of the tissue. 
To address this goal, superparamagnetic iron oxide nanoparticles (SPIONS) were first 
embedded in a mesoporous silica matrix and then, the external silica surface was coated with a 
thermosensitive polymer shell which acts as a gatekeeper of chemotherapeutic drugs trapped in 
the pore network. The AMF induces a change in the magnetic moment orientation inside the 
magnetic nanocrystals, that cause energy losses traduced in heat dissipation though the Néel 
relaxation mechanism.20 The temperature rise inside the nanocarrier reaches the 
thermoresponsive polymer layer which suffers a hydrophilic to hydrophobic transition. The 
polymer shrinking creates open spaces in the polymer barrier that allows the drug departure to 
the cancer tissue at the same time that the heat shock produce the cell damage, making cells more 
sensitive to chemotherapeutic agents (Scheme 1).37 Recently, our teams have demonstrated in 
Page 4 of 30
ACS Paragon Plus Environment
ACS Applied Materials & Interfaces
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 5 
vitro the capacity of this nanodevice to release drugs under AMF exposition without the need to 
increase the temperature macroscopically.38 However, the capability to trigger the delivery of 
small drugs under AMF within a living body was still untested in this kind of devices. This fact 
is even more exciting considering that the in vivo release was accomplished using low amounts 
of MNPs, which makes unnecessary to employ high doses of magnetic payload to trigger the 
drug release by increasing the macroscopic temperature in the cancer tissue.31 
The novelty of this study is grounded in several facts as: (1) the first reported in vivo 
evaluation of magnetically-triggerable MSN based nanomaterial which can produce a heat shock 
that activates the polymeric gate within a tissue; (2) that release a potent cytotoxic compound as 
doxorubicin, that provokes a significant tumor growth inhibition in 48 h only when AMF was 
applied; (3) taking into account that this inhibition was achieved at low magnetic doses without a 
global temperature rise, which (4) proves the synergic effect of magnetic hyperthermia (MH) and 
chemotherapy. This device also showed a remarkably high tissue penetration and low toxicity 
without the AMF application, which are important properties for drug delivery nanocarriers. It is 
also relevant to consider that this device has many opportunities for the improvement, e. g. 
employing its magnetic targeting capability or the chemical attachment of active targeting 
moieties in its surface. 
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 6 
 
Scheme 1. The nanocarriers is diffused in the cancer tissue after intratumoral injection and 
release its drug cargo when AMF is applied, provoking the tumor cell death. 
RESULTS AND DISCUSSION 
The synthesis of MMSNs coated with the thermosensitive polymer has been carried out 
following a method previously reported by our group.38 Briefly, SPIONs were synthesized by co-
precipitation of iron chloride salts in the presence of oleic acid (OA), obtaining stable 
hydrophobic magnetic nanoparticles with 9 nm size distribution and superparamagnetic 
behavior. The SPIONS were transferred to aqueous media with hexadecyltrimethylammonium 
bromide (CTAB), which also acted as a structure directing agent in the silica growth step by 
adding TEOS dropwise in the SPION suspension at basic pH.39 The silica surface was 
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 7 
functionalized in situ with small poly (ethylene glycol) chains to confer colloidal stability to the 
nanocarrier.40 Straightaway the silica surface was decorated with polymerizable groups with 3-
[tris(trimethylsiloxy)silyl]propyl methacrylate (MPS) and the CTAB surfactant was extracted by 
ion exchange to obtain MMSN-MPS precursor. Then, a radical polymerization was performed 
with N-isopropylacrylamide (NIPAM), N- (hydroxymethyl)acrylamide (NHMA) and N, N’-
methylenebis(acrylamide) (MBA) monomers in the presence of MMSNPs and ammonium 
persulfate (APS) as radical initiator, obtaining a polymer shell on the nanoparticles surface 
(Scheme in Figure 1). The polymer shell was designed to have a lower critical solution 
temperature (LCST) at 42 ˚C by controlling the ratio between its two main monomers. The 
LCST is the transition temperature which the polymer suffers a change from hydrophilic to 
hydrophobic state. This fact means that below the LCST the polymer chains will form a mesh 
that blocks the pore openings keeping the drug inside the silica matrix. When the temperature on 
the nanocarrier surroundings overcomes the transition temperature, the polymer suffers a 
collapse creating gaps in its structure and therefore allowing the drug release. 
Both, precursor MMSN-MPS and magnetic mesoporous nanocarriers coated with the 
thermoresponsive polymer (MMSN@TRP) were characterized (see supporting information and 
reference 26 for full characterization of each synthetic step). TEM images shows round-like 
shape particles with porous structure and SPIONs in their core (Figure 1a), while DLS 
measurements revealed a hydrodynamic size distribution shift up to 160 nm after the 
polymerization step (Figure 1b), which is in accordance with the polymer shell formation. A 20 
% of weight loss measured by TGA is associated with the grafted polymer and the FT-IR 
revealed a band at 1650 cm−1, which is characteristic of amide bond stretching (νNC=O) band that 
confirms the presence of the polymeric shell in the device. 
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 8 
 
Figure 1. Scheme of the synthetic route of MMSN@TRP. a) TEM image of the nanocarriers 
coated with thermoresponsive polymer and SPIONS placed inside the silica matrix and b) 
hydrodynamic size of the precursor (MMSN-MPS, blue line) and the final nanocarrier 
(MMSN@TRP, orange line). 
The iron determination revealed the ratio between the global material mass and the iron 
content, which is about 95.5 μg Fe·mg-1 material. The textural parameters and the magnetic 
heating properties were evaluated, confirming the drug loading capacity of the nanocarrier and a 
specific absorption rate (SAR) of 178,5 W·g Fe−1 as reported before,38 which generates the 
required heat dissipation to reach the polymer shell and trigger the release mechanism. Also the 
drug loading capacity was estimated by UV vis measurements at 520 nm of the doxorrubicin 
loaded and empty nanocarrier at two different concentrations, showing a 2.5 % wt of drug cargo. 
The experimental in vivo protocol to obtain the animal model is represented in the Figure 2 
and details are given in the experimental section. The selected tumor model is an allograft model 
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 9 
grown in a very commonly used immunocompetent mouse strain, C57/BL6. Most of the 
magnetic hyperthermia in vivo studies described in the literature use human tumor cell lines 
implanted in mice, i. e. xenograft tumor models, but this approach requires to use 
immunodeficient mice strains.41–45 Although these are the easiest in vivo models for pre-clinical 
human tumors studies, they have the disadvantage of lacking the complete effect of the immune 
system. A deficient immune system, which usually plays a key role to combat diseases, could 
negatively influence the treatments underestimating the real effect. On the contrary, the selected 
tumor model, C57/BL6, has the advantage of a complete immune response but also some 
disadvantages, like having to use murine cells lines instead human cell lines, and the fact that 
allogaft tumor models usually grow very fast and the time window of study is limited, because 
usually the tumors ulcerate even when they are not very big.  
One of the major problems to overcome when performing in vivo experiments using 
nanoparticles consists on the poor amount of material that reaches the desired location after 
systemic administration. And so it is when talking about the magnetic hyperthermia approach 
where the amount of magnetic material needed to release enough heat to kill cancer cells is 
usually high. This presents a real problem for many biological applications. Besides, there is a 
recent study that, after revising more than one hundred of papers, concluded that less than 1% of 
the intravenously administered dose arrives the tumor.46 This is the reason why the majority of 
the published studies use the direct injection of the magnetic material at the tumor site as the 
main route of administration, trying to get the maximum MNPs content in the tumor site. 
However, this type of administration has the disadvantage that requires the establishment of 
subcutaneous tumors. Heterotopic tumors located outside the equivalent organ where the tumors 
should be grown, like subcutaneous implants, have the main drawback of having not a proper 
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 10 
tumor microenvironment. The interactions between the tumor and the surroundings affects tumor 
cell proliferation, levels of growth factors and nutrients, both during tumor angiogenesis and in 
its metastatic behavior. On the contrary, they have great advantages; they are very easy to handle 
and the good accessibility is of great help to assess the direct measurements to evaluate tumor 
growth progression. As can be seen in the Figure 2 murine melanoma EL4 cells were injected 
subcutaneously in 7-week-old female C57BL/6 mice and after one week the tumors had the 
enough volume to be detectable and to be able to inject intratumor the nanocarrier. 
 
Figure 2. Scheme of the experimental protocol to obtain the tumoral animal model and details 
about the MNP injection and AMF exposition 
Prior to the application of the treatment, the nanocarrier diffusion within the tumor tissue was 
tested with rhodamine tagged nanocarriers (MMSN-Rho@TRP). To make the device 
fluorescent, the surface of the uncoated MMSN-MPS precursor was decorated with APTES-
modified rhodamine B isothiocyanate, which anchors to the nanoparticle by its silanol groups. 
Then, the radical polymerization was carried out with the fluorescent precursor, obtaining the 
same polymeric coating on the silica surface as obtained before. 1 mg of material, which 
corresponds to about 95.5 μg of Fe, was injected per mice of a group of three, and 96 hours after 
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the injection mice were euthanatized by CO2 inhalation and the tumor was remove and fix in 4% 
of paraformaldehyde. The three tumors were prepared and ultrathin sections were stained with 
DAPI to study the penetration of the nanocarrier within the tumor. Even though the nanocarrier 
injection was performed just in one point of the tumor, they have deeply penetrated within the 
tumor as can be observed under confocal microscopy (Figure 3). Big accumulation is detected in 
two main regions, being the biggest one probably the injection point. It is appealing that the 
material is also easily found in the center of the tumor and even in the opposite edge. Therefore, 
the diffusion studies showed a remarkable tissue penetration for the polymeric coated 
nanocarrier. 
 
Figure 3. Confocal images of tumor slices after being stained with DAPI. Red fluorescence 
came from the Rho-nanocarriers.  
Once the good penetrability of the material was confirmed, the following experiments were 
based on the application of the MH and the study of the tumor growth. Mice were divided 
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 12 
randomly in six different groups, each of them composed by four mice. To be able to detect and 
corroborate the synergistic effect between the heat release by the MMSNs and the drug release 
many controls were needed. A scheme of the experimental design can be seen in the Figure 4. 
Two control group which no particles and no free drug was injected, one without exposition to 
the AMF (A) and another under AMF application (B). Another two group of mice were injected 
with the doxorubicin loaded nanocarrier, one without AMF exposition (C) while the other group 
was exposed to the AMF (D). A fifth group of mice helped to the analysis of the tumor response 
to a free doxorubicin dose corresponding to a 100% release of the drug cargo from the device 
without AMF exposition (E). The last group of mice were injected with the unloaded MMSNs 
(without doxorubicin) and submitted to the AMF (E) to test the efficacy of the nanocarrier due to 
the heat generation per se. The MH treatment was applied in those pertinent groups for 30 
minutes the day of the injection and two more consecutive days. 
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Figure 4. Experimental design of in vivo tests. A) Control group without AMF, B) control group 
with AMF, C) group with MMSNs-doxorubicin without AMF, D) group with MMSNs loaded 
with doxorubicin and exposed to AMF, E) group injected with free doxorubicin and F) group 
with MMSNs without doxorubicin exposed to AMF. Four mice composed each group.  
It is worthy to briefly discuss the experimental conditions of the AMF applied due to there is 
an open debate about the biological safety limits for the amplitude and the frequency of the 
AMF. The heat generation caused by the eddy currents is non-selective heating, being therefore 
not useful for therapeutic purpose. The eddy currents occurred during an AMF application 
prompted to Atkinson et al to establish the first biological limit of the product H×f in 4.85 108 
Am-1s-1 (where H is the amplitude and f the frequency of the magnetic field). Unlikely, this limit 
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was stated taking into account the general discomfort of patients that were receiving one hour of 
an AMF in the thorax area.47 Later on, Hergt and Durtz estimated this limit up to 5 109 A·m-1s-1 
for smaller coils. Most of the published work about in vivo MH experiments set up the conditions 
between these two limits, but there are a considerable number of preclinical studies that use 
parameters above the upper limit. In our case, the H×f product gives a reasonable value of 1.89 
109 A·m-1s-1 which places this treatment below the upper limit,48 having the possibility to 
enhance the antitumor efficacy by using 2-3 fold higher AMF parameters.  
Animal weights and the three dimensions of the tumor, height (h), width (w) and length (l) 
were daily controlled, and the volume of the tumor was calculated as the volume of an ellipsoid 
using the following formula: V= (π/6)×h×w×l. The tumor volume was monitored for each mouse 
every day of the treatment and normalized to the volume of the tumor the day of the MMSNs 
injection and first AMF application (day 1 in the experimental design) in order to evaluate the 
tumor growth. Figure 5 shows the evolution of the mean of the body weight of all the animals in 
each experimental group along the complete experiment. The results indicate that there are no 
acute toxic effects coming from any of the elements of the complete treatment that provokes 
changes in the weight of the animals.  
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Figure 5. Mean of the weight of the animals along the experiment. (N=4, GraphPad Prism 
v5.03). 
As can be seen in Figure 6, the Perls staining was also appropriate to detect de MNPs 
contained in the nanocarriers and therefore its penetration and distribution within the tumor in 
each single mouse which results to be very similar to the one observed in the Figure 3 discussed 
above. 
 
Figure 6. Perls staining (blue) of tumor slices from A) Control mice without nanocarriers and B) 
mice tumors injected with nanocarriers. Scale bar corresponds to 50 μm. In accordance with the 
diffusion studies, great results of tumor growth inhibition were obtained. Arrows indicate the 
presence of iron.  
In Figure 7 can be seen the tumor growth monitorization during the whole experiment, that is, 
from the first exposition to AMF to the mice sacrifice. There are no significant differences 
between the control groups and the group receiving the complete treatment at day 3, this is, the 
MMSNs heating and doxorubicin release after the last of the three consecutive MH applications. 
At the beginning of the experiment the tumor’s volume duplicates just in 48h, giving an idea of 
A	) B )
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the aggressiveness of the tumor model commented previously. However, exciting results were 
obtained 48h after the last AMF exposure due to the tumor growth was deferred. A statistical 
significant difference (p<0.001) exists between all of the control groups and the group receiving 
the complete treatment. The tumor volume of all the controls was doubled from day 3 to day 5 
whereas the tumor growth in the group with the complete treatment was inhibited. 
 
Figure 7. Tumor growth calculated as (Tumor Volume)/(Initial Tumor Volume). Day 3 
corresponds to the measurements after the last magnetic hyperthermia treatment. Day 5 
corresponds to 48h after the last magnetic hyperthermia treatment. N=4. *** p<0.001; two-way 
ANOVA, Bonferroni multiple comparison test. 
The therapeutic effect demonstrates that the heating effect of the nanocarrier under AMF 
overcomes the heat dissipation of the blood stream in vivo, provoking the polymer transition and 
therefore the drug departure. The therapeutic efficacy also supports that the drug departure is 
taking place from the inside of the silica pore network only when AMF was applied; otherwise 
the Dox loaded sample counterpart (without AMF application) must have the same therapeutic 
effect. Remarkably, this point supports the synergic effect of chemotherapy and hyperthermia, 
because both control groups which have been treated with AMF only or doxorubicin only did not 
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show any tumoral growth inhibition effect. With these results it have been demonstrated that this 
nanocarrier has a powerful antitumor effect combining both the heat and the drug released by the 
MMSNs (despite the temperature rise was not evaluated in vivo). 
The fact that none of the controls presented a growth inhibition effect is important indeed due to 
it implies an advantage over other systems in the literature that achieve the tumor growth 
inhibition in longer periods,36 or require longer MH treatment periods,44 even when a synergic 
treatment is applied.43,49 These recent published works have also the need of heating at 
hyperthermia level the tumor tissue to obtain a significant tumor growth inhibition or regression. 
In our case the inhibition was observed 48 h after the last MH treatment. To study the growth 
inhibition effect at longer times an animal model with a slower tumor development can be used 
and therefore to enhance the final effect by several AMF expositions. 
The absence of a growth inhibition effect in all the control groups can be based on the low 
amounts of nanocarrier used in this study. For that reason, the amount of injected drug has not a 
detectable effect or the drug leaking from the nanocarrier is blocked or very low without AMF 
revealing the absence of unspecific antitumor effect. Also the combination of a low amount of 
MMSNs and the type of AMF parameters did not provoke a global temperature increase that 
would produce per se a tumor growth inhibition. Finally, we can conclude that the proposed 
treatment could be a very useful tool to combat accessible tumors and there are still a lot of 
points of the approach that could be improved. 
SUMMARY 
In this work we study the final in vivo antitumoral effect of an innovative nanodevice under 
AMF treatment. This nanocarrier combines the heat release by magnetic nanoparticles and drug 
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release by a thermosensitive polymer. Evaluating the tumor growth, it has been demonstrated 
that there exists a synergistic effect between both the heat generation and the drug release. 
Interestingly, none of the controls, where the effect of single components was evaluated, 
produced any antitumor effect. It is worthy to mention that the AMF parameters used in this 
study are well below the biological safety limit of 5 109 Am-1s-1 and that the amount of MNPs 
injected per mice (182 g Fe/tumor) is low in comparison with the majority of similar 
experiments published. That is why, these results are very promising and they confirm that there 
is no need to inject a huge amount of MNPs in the tumor in order to highly increases the 
macroscopic temperature to provoke antitumor effect, but taking advantage of the synergistic 
effect between a very localize heating and drug delivery is a very good strategy. 
Despite the fact that there exist many knowledge gaps in the frame of in vivo MH applications, 
these results indicate that this nanocarrier and the proposed AMF treatment methodology have a 
great potential in the cancer treatment and it opens the possibility to further optimize and 
maximize the resulting treatment efficiency.  
 
EXPERIMENTAL SECTION 
Preparation of Hydrophobic Magnetite (OA-Fe3O4) NPs. Hydrophobic magnetite NPs were 
synthesized by one-pot chemical coprecipitation method. Deionized water was purged with 
nitrogen gas for 10 min. Then, 4.80 g of FeCl3•6H2O, 2.00 g FeCl2•4H2O, and 0.85 mL oleic 
acid were added to 30 mL of deionized water under nitrogen atmosphere with vigorous stirring. 
The mixture solution was heated to 90 ˚C. Then, 20 mL of ammonium hydroxide (14 wt %) was 
added rapidly to the solution, and it immediately turned black. The reaction was kept at 90 ˚C for 
2.5 h and then allowed to cool to room temperature. The black precipitate was collected by 
Page 18 of 30
ACS Paragon Plus Environment
ACS Applied Materials & Interfaces
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 19 
magnetic decantation and resuspended in chloroform with an end concentration of 62.6 mg·mL-1 
oleic acid-capped Fe3O4. 
Preparation of Mesoporous Magnetic Silica Nanoparticles (MMSNs). MMSNs were prepared 
through CTAB assisted iron oxide nanoparticle oil-to-water transfer followed by silica 
condensation a procedure described elsewhere. Briefly, 49.9 mg OA-Fe3O4 in CHCl3 were 
poured (0.8 mL,0.04 mL·min-1 rate) into a recipient containing 580 mg of CTAB dissolved in 10 
mL of H2O (mQ) under mechanical stirring in an ultrasound bath. Once the removal of the 
organic solvent was completed, the dispersion was added to a 250 mL round-bottom flask with 
86 mL NaOH (0.016M) solution at 45 ˚C and stirred at 600rpm. Then, the silica precursor 
mixture was added dropwise (1.2 mL of EtOH and 1 mL of TEOS at 0.25 mL·min-1 rate) and 15 
min later, 260 µL of PEG-Si were added, and the suspension was stirred for 2h. The reaction 
mixture was washed with H2O, and EtOH prior to the functionalization with 0.5 mL MPS in 150 
mL of EtOH (99.5%) stirring at 35 ˚C during 16h. The surfactant template of the methacrylate 
functionalized MMSNs was removed by ion exchange using 150mL of 10 g·L-1 NH4NO3 in 
EtOH (95%) extracting solution during 2 h at 65˚C two times and the brown suspension was 
washed by several centrifugation and decantation steps with EtOH and keep it wet and sealed. 
The MMSN-MPS mass determination was done by drying an aliquot of the last wash step, and 
the so-obtained brown solid was used for characterization. 
MMSNs Rhodamine labeling (MMSN-Rho). To anchor the dye to the MMSNs 2 mg of RITC 
were purged with nitrogen and 1 µL of APTES was added and stirred at r.t. during 1.5 h. At the 
same time, 150 mg of MMSN-MPS were centrifugated and the tube sealed to proceed with the 
N2 purge for water removal before the addition of 10 mL of dry toluene and the dispersion 
carried to a flask under nitrogen flow. Once the reaction of the dye was completed the entire 
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reaction mixture was added to the flask and the temperature raised to 80 ˚C and stirred during 16 
h. The excess of reactants was removed by washing one time with toluene and several times with 
ethanol until no dye is observed in the supernatant. 
MMSNs Polymer Coating. 142.5 mg (1.26 mmol) of NIPAM, 12 mg of MBA (0.078mmol), 
33.1 µL of NHMA (0.022 mmol, 48 %wt), 3.6 mg of CTAB and 5 mg of Na2CO3 were dissolved 
in 45 mL of water (mQ) and poured in a 100 mL three-neck round-bottom flask. The solution 
was stirred under N2 bubbling at 70 ˚C for 30 min to remove oxygen. Then, a dispersion of 50 
mg of MMSNs dispersed in 5 mL of EtOH (99.5%) purged with N2 was added to the monomer 
solution. The polymerization was initiated by the addition of 0.5 mL of a 10 mg·ml-1 APS 
solution in H2O (mQ) previously deoxygenated to the reaction mixture. Ten minutes later the 
reaction mixture was allowed to cool down to room temperature and kept at that temperature 
overnight. The mixture was centrifuged and washed with THF twice and three more times with 
EtOH to remove the unreacted monomers and the organic solvent obtaining the 
thermoresponsive canocarrier MMSN@TRP. 
MMSNs doxorubicin loading and drug cargo determination. Prior to the cargo loading the TR 
MMSN@TRP sample was washed with PBS (1x). Then, 50 mg of the solid were re-dispersed in 
a 1 mg·mL-1 solution of DOX in the same buffer and stirred for 24 h at 50 ˚C. The loaded 
MMSNs were washed by centrifugation with water and EtOH successively and dried in several 
aliquots under vacuum. For the DOX determination, two dispersions of the non-loaded (as a 
control) and drug-loaded nanocarriers at 0.1 mg·mL-1 and 0.5 mg·mL-1 were measured by UV-
vis at 520 nm. The results were interpolated into a DOX standard fitting in PBS (1x) showing a 
25 µg·mg-1 drug loading (2.5 % wt).  
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Cell line: EL4 murine lymphoma cell line from the strain C57BL/6N was cultured and 
maintained in RPMI1640 (Lonza) supplemented with 5% FBS () and 1% glutamine (Invitrogen) 
and 1% penicillin/streptomycin (Invitrogen). Cells were maintened in suspension in an incubator 
at 37ºC and in presence of 5% CO2. Every two days the cell culture was diluted 1:10.  
Animal model:  Pathogen-free female 6-week C57BL/6 mice were commercially obtained 
from Charles River Laboratory and were maintained in the Animal facilities of the CIBA (IACS-
Universidad de Zaragoza). Mice were held one week after arriving the animal facilities for 
acclimation. Animals were maintained according to the institutional animal use and care 
regulation of the Centro de Investigaciones Biomedicas de Aragón (CIBA, Zaragoza, Spain). All 
animal experiments were conducted according the law RD53/2013 and approved by the Ethics 
Committee for animal experiments from the University of Zaragoza that is an accredited animal-
welfare body. After the week of acclimation, 2,5 106 EL4 cells suspended in 100 L of sterile 
and complete culture medium without antibiotics were injected subcutaneously in the right flank 
of animals with a 25G needle. Before the injection the right flank of the animals was shaved. 
During the cells injection animals were anesthetized by inhalation of isoflurane (4% for the 
induction step and 2% for maintenance).  
MH treatment: After 7 days of cell injection, tumors were small but big enough to be detected 
and to inject MMSNs intratumorally. Mice were randomnly divided in 6 groups of 4 mice each.  
In experimental groups with MMSNs (both with and without doxorubicin), 50 L of sterile PBS 
containing 1mg of material were injected per mice (corresponds to about 182 g Fe/tumor) with 
a 30G needle. MMSNs injection was performed in one point of the tumor. In control group with 
free doxorubicin mice were injected with 50 L of 0,5 mg/mL doxorubicin in PBS (0,025 mg is 
the amount of doxorubicin calculated to be entrapted in 1 mg of material). The same day of 
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MMSNs injection and the following two days, mice were exposed to one AMF cycle. The device 
used for the AMF exposure was the model DM3 from nB nanoscale Biomagnetics (Zaragoza, 
Spain). Each exposure time was 30 min at 105 kHz and 18 kA·m-1. Mice were anesthetized with 
isoflurane and maintained during the AMF exposure onto a hot water bath system that prevents 
the mice to suffer hypothermia. Rectal temperature was registered during the AMF exposure to 
control general state of the animals. Tumor dimensions (length, with and height) and mice 
weight were daily measured with a Vernier. After the last AMF exposure mice were maintained 
3 days or until tumors started to ulcerate.  
Sample preparation and analyses: Mice were euthanasiated by CO2 inhalation and blood was 
directly extracted from the heart and tumor was removed and fixed in 4% PFA and processed to 
perform three different staining: Hematoxylin/Eosin staining, DAPI and Blue Perls staining. All 
the sample preparation from the fixation on was made by the “Servicio Científico Técnico – 
Microscopía y Anatomía Patológica” of the CIBA (IACS-Universidad de Zaragoza). Samples 
were observed under an inverted microscope (Nikon eclipse TE2000-S) and using a confocal 
microscopy (Olimpus FV10-I Oil Type). 
Characterization Techniques. Fourier transform infrared spectroscopy (FTIR) was carried out 
in a Thermo Nicolet nexus equipped with a Goldengate attenuated total reflectance device. 
Thermogravimetry analysis (TGA) were performed in a Perkin Elmer Pyris Diamond TG/DTA 
analyzer, with 5 °C min −1 heating ramps, from room temperature to 600 °C. The hydrodynamic 
size of mesoporous nanoparticles and SPION size were measured by means of a Zetasizer Nano 
ZS (Malvern Instruments) equipped with a 633 nm “red” laser. Transmission electron 
microscopy (TEM) was carried out with a JEOL JEM 2100 instruments operated at 200 kV, 
equipped with a CCD camera (KeenView Camera). Sample preparation was performed by 
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dispersing in MiliQ water (CHCl3 for OA-Fe3O4) and subsequent deposition onto carbon-coated 
copper grids. UV-Vis spectrometry was used to determine the doxorubicin amount in the 
nanocarriers by means of a Biotek Synergy 4 device. Iron quantification for SAR measurements 
was determined by measuring the absorbance at 480 nm on a Thermo Scientific Multiskan GO 
UV/Vis microplate spectrophotometer after performing an acidic digestion and oxidation of the 
iron content of the material to Fe3+ and coupling it to 4,5-Dihydroxy-1,3-benzenedisulfonic acid 
disodium salt (TIRON, Sigma Aldrich) reagent. A calibration curve was performed following the 
same procedure using iron standard solution (Acros Organics) as reference. The SAR, 
measurements were performed on a DM100 system (nanoScale Biomagnetics) in the frequency 
range from 424 kHz to 838 kHz and magnetic fields of 20.05 to 23.87 kA·m−1. The textural 
properties of the materials were determined by nitrogen sorption porosimetry by using a 
Micromeritics ASAP 2020. To perform the N2 measurements, the samples were previously 
degassed under vacuum for 24 h at room temperature. 
Calculation Procedures: The SAR calculations were performed by DM100 system software 
(nanoScale Biomagnetics). All the statistics studies have been made using the GraphPad Prism 
v5.03 software. To calculate the p value the used test was two-way ANOVA, Bonferroni 
multiple comparison test. The surface area was determined using the Brunauer-Emmett-Teller 
(BET) method and the pore volume, Vpore (cm3·g−1), was estimated from the amount of N2 
adsorbed at a relative pressure around 0.99. The pore size distribution between 0.5 and 40 nm 
was calculated from the desorption branch of the isotherm by means of the Barrett-Joyner-
Halenda (BJH) method. The mesopore size, Øpore (nm), was determined from the maximum of 
the pore size distribution curve. 
AUTHOR INFORMATION 
Page 23 of 30
ACS Paragon Plus Environment
ACS Applied Materials & Interfaces
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 24 
Corresponding Authors 
E-mail: vallet@ucm.es, abaezaga@ucm.es 
Present Addresses 
† Dr. E. Guisasola is now located at CIC Biomagune, Paseo Miramón 182, 20009  
Donostia/San Sebastián (Gipuzkoa) 
Author Contributions 
The manuscript was written through contributions of all authors. All authors have given approval 
to the final version of the manuscript. 
Funding Sources 
The present work was supported by grants from European Research Council (Advanced Grant 
VERDI; ERC-2015-AdG Proposal No. 694160) the Spanish MINECO project MAT2015-64831-
R, SAF2014-54763-C2-2-R, Fondo Social de la DGA (grupos DGA) and COST Action TD1402 
Radiomag 
 
ACKNOWLEDGMENT 
This work was supported by the European Research Council (Advanced Grant VERDI; ERC-
2015-AdG Proposal No. 694160) and the project MAT2015-64831-R. LB thanks Santander-
Universidad Zaragoza Fellowship program for her PhD position. LA thanks Juan de la Cierva 
Program for her postdoctoral possition. Authors would like to acknowledge the use of Servicios 
Científicos Técnicos del CIBA (IACS-Universidad de Zaragoza).  
 
ABBREVIATIONS 
Page 24 of 30
ACS Paragon Plus Environment
ACS Applied Materials & Interfaces
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 25 
MMSNs, magnetic mesoporous silica nanoparticles; AMF, alternating magnetic field; EPR, 
enhanced permeation and retention; MSNs, mesoporous silica nanoparticles; MNPs, magnetic 
nanoparticles; SPIONS, superparamagnetic iron oxide nanoparticles; MH, magnetic 
nanoparticles; OA, oleic acid; CTAB, hexadecyltrimethylammonium bromide; NIPAM, N-
isopropylacrylamide; NHMA, N- (hydroxymethyl)acrylamide; MBA, N, N’-
methylenebis(acrylamide); APS, ammonium persulfate; LCST, lower critical solution.    
ASSOCIATED CONTENT 
Additional characterization of the devices used in this work is supplied as Supporting 
Information. The full characterization can be found in reference 38. 
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Tumor growth inhibition in vivo is achieved in 48 hours by a synergic effect between 
nanoscale hyperthermia and chemotherapy with magnetic-responsive mesoporous silica 
nanocarriers. The treatment is triggered by AMF application, and demonstrates that the 
nanocarrier heating overcomes the heat dissipation of the blood stream in vivo, provoking the 
polymer transition and therefore the drug release. 
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